CC BY 4.0 · Surg J (N Y) 2019; 05(01): e1-e4
DOI: 10.1055/s-0038-1677483
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Urinary N-telopeptide: The New Diagnostic Test for Osteoporosis

Ganesan Ram Ganesan
1   Department of Orthopaedics, Sri Ramachandra University, Chennai, Tamil Nadu, India
,
Phagal Varthi Vijayaraghavan
1   Department of Orthopaedics, Sri Ramachandra University, Chennai, Tamil Nadu, India
› Author Affiliations
Further Information

Publication History

27 May 2018

04 December 2018

Publication Date:
08 January 2019 (online)

Abstract

Context Osteoporosis is a silent disease until it is complicated by trivial fall fractures. There is an increasing interest within the orthopaedic community in the noninvasive cost-effective measurement of the bone mineral density.

Aims The aim of the study is to assess whether urinary N-telopeptide level can be a new diagnostic tool in diagnosing osteoporosis.

Methods and Material This prospective study was done at Sri Ramachandra Medical Centre (SRMC) hospital from October 2015 to October 2017. The study was conducted among patients who comes to SRMC as inpatient or outpatient with suspected osteoporosis and underwent dual-energy X-ray absorptiometry (DXA) scan and urinary N-telopeptide. The inclusion criteria were women aged 65 or older, women aged less than 65 with risk factors, younger postmenopausal women with one or more risk factors, men aged 70 or older, men less than 70 with risk factors, and any above group patients who comes within 24 hours following trivial fall fractures. The exclusion criteria were pathological fracture, history of any illness affecting bone metabolism. The results from DXA scan were taken as gold standard against urinary N-telopeptide. Then the patients were divided into two groups control and study. The control group contains patients who had normal DXA, while study group contains patients having either osteopenia or osteoporosis. Based on our inclusion and exclusion criteria, 110 persons were included in the study. We had 60 study and 50 controls patients. We had 88 females and 22 males. The results obtained were statistically analyzed.

Statistical Analysis Used The collected data were analyzed with IBM SPSS statistics software 23.0 version. To describe about the data descriptive statistics frequency analysis, percentage analysis was used for categorical variables and the mean and standard deviation were used for continuous variables. To find the significant difference between the bivariate samples in independent groups, the unpaired sample t-test was used. To find the significance in categorical data, chi-square test was used. In both the earlier statistical tools, the probability value of 0.05 is considered as significant level.

Results In our study, we had 18.2% osteopenic and 36.4% osteoporotic patients. The mean value of urinary N-telopeptide in control was 49.8 and in case was 182.5. The standard deviation of urinary N-telopeptide value in case was 159.9.

Conclusion Urinary N-telopeptide can give reproducible results and be able to assist in the evaluation of the quantity as well as the quality and be a good judge of someone's risk of fracture. Hence, urinary N-telopeptide can be used as a diagnostic tool for diagnosing osteoporosis.

 
  • References

  • 1 Shepherd AJ, Cass AR, Carlson CA, Ray L. Development and internal validation of the male osteoporosis risk estimation score. Ann Fam Med 2007; 5 (06) 540-546
  • 2 Cianferotti L, Brandi ML. Guidance for the diagnosis, prevention and therapy of osteoporosis in Italy. Clin Cases Miner Bone Metab 2012; 9 (03) 170-178
  • 3 Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149 (11) 2445-2448
  • 4 Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med 1986; 314 (26) 1676-1686
  • 5 Punda M, Grazio S. Bone densitometry--the gold standard for diagnosis of osteoporosis [in Croatian]. Reumatizam 2014; 61 (02) 70-74
  • 6 Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch Intern Med 1997; 157 (11) 1241-1245
  • 7 Sievänen H, Oja P, Vuori I. Precision of dual-energy x-ray absorptiometry in determining bone mineral density and content of various skeletal sites. J Nucl Med 1992; 33 (06) 1137-1142
  • 8 Institute of Medicine (US) Committee on Military Nutrition Research. Carlson-Newberry SJ, Costello RB, eds. Emerging Technologies for Nutrition Research: Potential for Assessing Military Performance Capability. Washington, DC: National Academies Press (US); 1997. 6, Dual-Energy X-Ray Absorptiometry: Research Issues and Equipment. Available at: https://www.ncbi.nlm.nih.gov/books/NBK233779/ . Accessed January 2, 2019
  • 9 Rothney MP, Brychta RJ, Schaefer EV, Chen KY, Skarulis MC. Body composition measured by dual-energy X-ray absorptiometry half-body scans in obese adults. Obesity (Silver Spring) 2009; 17 (06) 1281-1286
  • 10 Kleerekoper M, Edelson GW. Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. Endocr Pract 1996; 2 (01) 13-19
  • 11 Jayaram N, Bijoor AR, Rajagopalan N, Venkatesh T. The value of serum and urinary n-telopeptide in the diagnosis of osteoporosis. Indian J Orthop 2002; 36: 9-13
  • 12 Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med 2008; 75 (10) 739-750
  • 13 Bettica P, Moro L, Robins SP. , et al. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin Chem 1992; 38 (11) 2313-2318